Replies to post #784613 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

There’s so much to unpack here.

Advent and NWBO were always two halves of the same strategy: product + manufacturing. With UK approval in sight, merging Advent under the same roof makes NWBO a clean, de-risked package for a larger pharma or institutional investor. Whether the White Paper spells it out directly or not, the Advent deal only strengthens the buyout/partnership case. It’s about presenting an integrated asset.

Of course, approval is a given now — there is absolutely no doubt. Had there been no approval, Powers would never have merged the two and risked letting the jewel, Advent, sink with NWBO to the bottom of the ocean. There’s also the 15% leeway now, which gives NWBO a stronger negotiating position toward NICE.

There is absolute confidence that NWBO, plus roughly 90 highly trained staff, can be sustained in the coming months. And as I’ve already said: the senior leadership is in place, but there is a complete absence of sales and sales support.

So in my view, everything points toward a future buyout.